|
|
Article: PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy.(Clinical report)
- Article from:
- Biotech Week
- Article date:
- February 18, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PTC Therapeutics, Inc. (PTC) announced that it has successfully completed patient enrollment of its pivotal clinical trial of PTC124 in patients with nonsense mutation Duchenne and Becker muscular dystrophy (nmDMD/BMD). Accrual was completed two months ahead of schedule. The company also announced that PTC124 has been issued the generic name, ataluren (see also Muscular Dystrophy).
The one-year, multi-center, randomized, double-blind, placebo-controlled study is designed to determine whether ataluren can improve walking, muscle function and strength in patients with nmDMD/BMD. It will also evaluate ataluren's long-term safety profile over a longer term than in ...